240 related articles for article (PubMed ID: 15381637)
1. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.
Wiley KE; Davenport AP
Br J Pharmacol; 2004 Oct; 143(4):508-14. PubMed ID: 15381637
[TBL] [Abstract][Full Text] [Related]
2. Urocortin-induced relaxation in the human internal mammary artery.
Chen ZW; Huang Y; Yang Q; Li X; Wei W; He GW
Cardiovasc Res; 2005 Mar; 65(4):913-20. PubMed ID: 15721872
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
Okada R; Miller MF; Yamamoto K; De Groef B; Denver RJ; Kikuyama S
Gen Comp Endocrinol; 2007 Feb; 150(3):437-44. PubMed ID: 17188689
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
5. Urocortin and cardiovascular protection.
Huang Y; Yao XQ; Lau CW; Chan YC; Tsang SY; Chan FL
Acta Pharmacol Sin; 2004 Mar; 25(3):257-65. PubMed ID: 15000874
[TBL] [Abstract][Full Text] [Related]
6. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
7. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery.
Schilling L; Kanzler C; Schmiedek P; Ehrenreich H
Br J Pharmacol; 1998 Nov; 125(6):1164-71. PubMed ID: 9863643
[TBL] [Abstract][Full Text] [Related]
9. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW
J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
[TBL] [Abstract][Full Text] [Related]
10. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system.
Hashimoto K; Nishiyama M; Tanaka Y; Noguchi T; Asaba K; Hossein PN; Nishioka T; Makino S
Peptides; 2004 Oct; 25(10):1711-21. PubMed ID: 15476938
[TBL] [Abstract][Full Text] [Related]
11. Urocortins of the South African clawed frog, Xenopus laevis: conservation of structure and function in tetrapod evolution.
Boorse GC; Crespi EJ; Dautzenberg FM; Denver RJ
Endocrinology; 2005 Nov; 146(11):4851-60. PubMed ID: 16037378
[TBL] [Abstract][Full Text] [Related]
12. Microinjection of urocortin into the rat nucleus tractus solitarii decreases arterial blood pressure.
Yamazaki T; Waki H; Kohsaka A; Nakamura T; Cui H; Yukawa K; Maeda M
Auton Neurosci; 2008 Nov; 142(1-2):51-4. PubMed ID: 18804421
[TBL] [Abstract][Full Text] [Related]
13. Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors.
Suda T; Kageyama K; Sakihara S; Nigawara T
Peptides; 2004 Oct; 25(10):1689-701. PubMed ID: 15476936
[TBL] [Abstract][Full Text] [Related]
14. Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat.
Mackay KB; Stiefel TH; Ling N; Foster AC
Eur J Pharmacol; 2003 May; 469(1-3):111-5. PubMed ID: 12782192
[TBL] [Abstract][Full Text] [Related]
15. Effect of central corticotropin releasing factor on hepatic circulation in rats: the role of the CRF2 receptor in the brain.
Yoneda M; Nakamura K; Nakade Y; Tamano M; Kono T; Watanobe H; Shimada T; Hiraishi H; Terano A
Gut; 2005 Feb; 54(2):282-8. PubMed ID: 15647195
[TBL] [Abstract][Full Text] [Related]
16. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart.
Kimura Y; Takahashi K; Totsune K; Muramatsu Y; Kaneko C; Darnel AD; Suzuki T; Ebina M; Nukiwa T; Sasano H
J Clin Endocrinol Metab; 2002 Jan; 87(1):340-6. PubMed ID: 11788672
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.
Wiley KE; Davenport AP
Br J Pharmacol; 2002 Aug; 136(8):1146-52. PubMed ID: 12163347
[TBL] [Abstract][Full Text] [Related]
18. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
19. Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats.
Gardiner SM; March JE; Kemp PA; Davenport AP; Wiley KE; Bennett T
J Pharmacol Exp Ther; 2005 Jan; 312(1):53-60. PubMed ID: 15328375
[TBL] [Abstract][Full Text] [Related]
20. Regulation of corticotropin-releasing factor receptor type 2 beta messenger ribonucleic acid in the rat cardiovascular system by urocortin, glucocorticoids, and cytokines.
Kageyama K; Gaudriault GE; Bradbury MJ; Vale WW
Endocrinology; 2000 Jul; 141(7):2285-93. PubMed ID: 10875227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
